Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis
Bevacizumab Versus Cidofovir for the Treatment of Recurrent Respiratory Papillomatosis: a Randomized, Double-blind, Placebo-controlled Clinical Trial
Sponsor: Centro de Investigación en. Enfermedades Infecciosas, Mexico
A PHASE2 clinical study on Recurrent Respiratory Papillomatosis, this trial is ongoing. The trial is conducted by Centro de Investigación en. Enfermedades Infecciosas, Mexico and has accumulated 7 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Aug 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
▶ Show 2 earlier versions
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Recruiting PHASE2
First recorded
Dec 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • México, Mexico